Optoceutics Aps

Development in activities and financial positionThe Company's income statement for 2022 shows a loss of DKK 3,635,660 as against a loss of DKK 3,880,378 in 2021. Equity in the Company's balance sheet at 31 December 2022 stood at DKK 16,943,109 as against DKK 13,367,310 at 31 December 2021.Capital resourcesOptoCeutics is still in development mode, incurring high research and development costs which is still running in the minus in terms of cost and revenue. We know we have a long and costly road ahead as our device enters the market but we are encouraged through the results of our preliminary sales that there is a market and need for our devices. It’s only a matter of time until the rest of the world catches on. The work above accounts for the exciting clinical and financial progress in Optoceutics, and is a result of the exceptional support of our shareholders and of the outstanding work of our daily team.